Meeting Banner
Abstract #0186

Ferumoxytol-enhanced Pulmonary MRA in Pregnancy: Evaluation of Initial Safety and Image Quality

Jitka Starekova1, Scott K Nagle1, Mark L Schiebler1, Scott B Reeder1,2,3,4,5, and Venkata N Meduri1
1Radiology, University of Wisconsin-Madison, Madison, WI, United States, 2Medicine, University of Wisconsin-Madison, Madison, WI, United States, 3Medical Physics, University of Wisconsin-Madison, Madison, WI, United States, 4Biomedical Engineering, University of Wisconsin-Madison, Madison, WI, United States, 5Emergency Medicine, University of Wisconsin-Madison, Madison, WI, United States

Ferumoxytol (Feraheme®, AMAG Pharmaceuticals, Waltham) is an injectable iron micro particle-solution approved by the FDA for treatment of iron-deficiency anemia. This medication also has favorable properties as intravascular blood pool agent (off-label) for contrast-enhanced MRA (Fe-MRA). Fe-MRA is an alternative modality for the assessment of pulmonary embolism without the need for ionizing radiation or gadolinium in pregnant patients. The purpose of this study was to summarize our clinical experience with 70 Fe-MRA exams in 66 pregnant patients. We aimed to demonstrate the safety and efficacy of Fe-MRA and provide guidance in establishing a clinical service.

This abstract and the presentation materials are available to members only; a login is required.

Join Here